PLK4 inhibition: a new therapeutic for AML
PLK4 inhibition could be a novel therapeutic for an acute myeloid leukaemia subtype carrying the TP53 mutation.
List view / Grid view
PLK4 inhibition could be a novel therapeutic for an acute myeloid leukaemia subtype carrying the TP53 mutation.
A patient-specific organ-on-a-chip model of cholangiocarcinoma, with its tumour microenvironment, helps to predict therapy response.
Inhibiting mTOR signalling and neutralising mtROS suppressed MCC-PD-1-mediated tumour proliferation in mice.
In this exclusive interview, Dr Espen Basmo Ellingsen, a luminary in cancer immunology, provides insights into the anticipated breakthroughs, collaborative endeavours, and personalised strategies that promise to elevate the effectiveness and durability of immuno-oncology interventions.
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
The ML algorithm explores how genetic mutations collectively influence a tumour’s reaction to drugs impeding DNA replication.
Using an AI algorithm to predict glioblastoma’s most active kinase, researchers hope for a next-generation precision therapy targeting resistant cancers.
Researchers discover a key metabolic process that cancer cells use to grow in a nutrient deprived environment, which could be a new target.
In this Q&A, Dr Lev Becker, Associate Professor, University of Chicago and Cofounder of Onchilles Pharma, reveals how his company is directing research into neutrophil biology to the advantage of cancer patients that need it most.
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.
A new blood panel test reports the tumour fraction and the tumour type of prostate cancer with a high level of accuracy.
Novel self-assembled amino acid-based nanoparticles, loaded with doxorubicin, could evolve cancer treatment.
Explore the history and trends of microscopy in cancer research and discover the latest cancer imaging solutions and techniques in this eBook.
Using bioinformatics analyses, HK-CREs impact on cellular processes was studied, including their potential as housekeeping tumour suppressors.
A new study could result in CTLA-4 inhibitors that promote antitumour responses without causing intestinal diseases, such as colitis.